datamatters24/research-document-archive huggingface dataset:
II 
Calendar No. 312 
110TH CONGRESS 
1ST SESSION H. R. 2563 
IN THE SENATE OF THE UNITED STATES 
JUNE 19, 2007 
Received; read twice and referred to the Committee on Homeland Security and 
Governmental Affairs 
AUGUST 1, 2007 
Reported by Mr. LIEBERMAN, without amendment 
AN ACT 
To designate the facility of the United States Postal Service 
located at 309 East Linn Street in Marshalltown, Iowa, 
as the ‘‘Major Scott Nisely Post Office’’. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. MAJOR SCOTT NISELY POST OFFICE. 
(a) DESIGNATION.—The facility of the United States 
Postal Service located at 309 East Linn Street in 
Marshalltown, Iowa, shall be known and designated as the 
‘‘Major Scott Nisely Post Office’’. 
VerDate Aug 31 2005 
05:47 Aug 02, 2007
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H2563.RS
H2563
bajohnson on PROD1PC69 with BILLS
(b) REFERENCES.—Any reference in a law, map, reg-
ulation, document, paper, or other record of the United 
States to the facility referred to in subsection (a) shall 
be deemed to be a reference to the ‘‘Major Scott Nisely 
Post Office’’. 
VerDate Aug 31 2005 
05:47 Aug 02, 2007
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H2563.RS
H2563
bajohnson on PROD1PC69 with BILLS
VerDate Aug 31 2005 
05:47 Aug 02, 2007
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H2563.RS
H2563
bajohnson on PROD1PC69 with BILLS
Calendar No. 312 
110TH CONGRESS 
1ST SESSION 
H. R. 2563 
AN ACT 
To designate the facility of the United States Post-
al Service located at 309 East Linn Street in 
Marshalltown, Iowa, as the ‘‘Major Scott Nisely 
Post Office’’. 
AUGUST 1, 2007 
Reported without amendment 
VerDate Aug 31 2005 
05:47 Aug 02, 2007
Jkt 059200
PO 00000
Frm 00004
Fmt 6651
Sfmt 6651
E:\BILLS\H2563.RS
H2563
bajohnson on PROD1PC69 with BILLS
206 
‘‘(ii) A summary that is written in 
non-technical, understandable language for 
patients that includes the following: 
‘‘(I) The purpose of the clinical 
trial. 
‘‘(II) The sponsor of the clinical 
trial. 
‘‘(III) A point of contact for in-
formation about the clinical trial. 
‘‘(IV) A description of the patient 
population tested in the clinical trial. 
‘‘(V) A general description of the 
clinical trial and results, including a 
description of and the reasons for any 
changes in the clinical trial design 
that occurred since the date of sub-
mission of clinical trial information 
for inclusion in the registry database 
established under subsection (b) and a 
description of any significant safety 
information. 
‘‘(iii) A summary that is technical in 
nature that includes the following: 
‘‘(I) The purpose of the clinical 
trial. 
VerDate Aug 31 2005 
05:37 Jul 12, 2007
Jkt 059200
PO 00000
Frm 00206
Fmt 6652
Sfmt 6201
E:\BILLS\H2900.RH
H2900
bajohnson on PROD1PC77 with BILLS
of development) with a human or predominantly 
human genetic constitution. 
‘‘(2) SOMATIC CELL.—The term ‘somatic cell’ 
means a diploid cell (having a complete set of chro-
mosomes) obtained or derived from a living or de-
ceased human body at any stage of development. 
‘‘§ 302. Prohibition on human cloning 
‘‘(a) IN GENERAL.—It shall be unlawful for any per-
son or entity, public or private, in or affecting interstate 
commerce— 
‘‘(1) to perform or attempt to perform human 
cloning; 
‘‘(2) to participate in an attempt to perform 
human cloning; or 
‘‘(3) to ship or receive the product of human 
cloning for any purpose. 
‘‘(b) IMPORTATION.—It shall be unlawful for any per-
son or entity, public or private, to import the product of 
human cloning for any purpose. 
‘‘(c) PENALTIES.— 
‘‘(1) IN GENERAL.—Any person or entity that 
is convicted of violating any provision of this section 
shall be fined under this section or imprisoned not 
more than 10 years, or both. 
VerDate Aug 31 2005 
20:47 Jun 06, 2007
Jkt 059200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H2564.IH
H2564
jlentini on PROD1PC65 with BILLS
‘‘(2) CIVIL
PENALTY.—Any person or entity 
that is convicted of violating any provision of this 
section shall be subject to, in the case of a violation 
that involves the derivation of a pecuniary gain, a 
civil penalty of not less than $1,000,000 and not 
more than an amount equal to the amount of the 
gross gain multiplied by 2, if that amount is greater 
than $1,000,000. 
‘‘(d) SCIENTIFIC RESEARCH.—Nothing in this sec-
tion shall restrict areas of scientific research not specifi-
cally prohibited by this section, including research in the 
use of nuclear transfer or other cloning techniques to 
produce molecules, DNA, cells other than human embryos, 
tissues, organs, plants, or animals other than humans.’’. 
(b) CLERICAL AMENDMENT.—The table of chapters 
for part I of title 18, United States Code, is amended by 
inserting after the item relating to chapter 15 the fol-
lowing: 
‘‘16. Human Cloning ..........................................................................
301’’. 
Æ 
VerDate Aug 31 2005 
20:47 Jun 06, 2007
Jkt 059200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6301
E:\BILLS\H2564.IH
H2564
jlentini on PROD1PC65 with BILLS
212 
status of the drug or device involved, an 
update informing the Director of NIH of 
such change. 
‘‘(5) TRUTHFUL
CLINICAL
TRIAL
INFORMA-
TION.— 
‘‘(A) IN GENERAL.—The clinical trial in-
formation submitted by a responsible party 
under this subsection shall not be false or mis-
leading in any particular. 
‘‘(B) EFFECT.—Subparagraph (A) shall 
not have the effect of requiring clinical trial in-
formation with respect to a clinical trial to in-
clude information from any source other than 
such clinical trial. 
‘‘(6) PUBLIC AVAILABILITY OF RESULTS.— 
‘‘(A) PRE-APPROVAL STUDIES.—Except as 
provided in subparagraph (E), with respect to 
an applicable clinical trial that is completed be-
fore the drug is initially approved under section 
505 of the Federal Food, Drug, and Cosmetic 
Act or initially licensed under section 351 of 
this Act, or the device is initially cleared under 
section 510(k) or approved under section 515 of 
the Federal Food, Drug, and Cosmetic Act, the 
Director of NIH shall make publicly available 
VerDate Aug 31 2005 
05:37 Jul 12, 2007
Jkt 059200
PO 00000
Frm 00212
Fmt 6652
Sfmt 6201
E:\BILLS\H2900.RH
H2900
bajohnson on PROD1PC77 with BILLS
213 
on the results database the clinical trial infor-
mation submitted for such clinical trial not 
later than 30 days after— 
‘‘(i) the drug or device is approved 
under such section 505, licensed under 
such section 351, cleared under such sec-
tion 510(k), or approved under such sec-
tion 515, as applicable; or 
‘‘(ii) the Secretary issues a not ap-
provable letter or a not substantially equiv-
alent letter for the drug or device under 
such section 505, 351, 510(k), or 515, as 
applicable. 
‘‘(B) MEDICAL
AND
CLINICAL
PHARMA-
COLOGY
REVIEWS
OF
PRE-APPROVAL
STUD-
IES.—Not later than 90 days after the date ap-
plicable under clause (i) or (ii) of subparagraph 
(A) with respect to an applicable clinical trial, 
the Director of NIH shall make publicly avail-
able on the results database a summary of the 
available medical and clinical pharmacology re-
views conducted by the Food and Drug Admin-
istration for such trial. 
‘‘(C) POST-APPROVAL
STUDIES.—Except 
as provided in subparagraphs (D) and (E), with 
VerDate Aug 31 2005 
05:37 Jul 12, 2007
Jkt 059200
PO 00000
Frm 00213
Fmt 6652
Sfmt 6201
E:\BILLS\H2900.RH
H2900
bajohnson on PROD1PC77 with BILLS
214 
respect to an applicable clinical trial that is 
completed after the drug is initially approved 
under such section 505 or licensed under such 
section 351, or the device is initially cleared 
under such section 510(k) or approved under 
such section 515, the Director of NIH shall 
make publicly available on the results database 
the clinical trial information submitted for such 
clinical trial not later than 30 days after the 
date of such submission. 
‘‘(D) SEEKING APPROVAL OF A NEW USE 
FOR THE DRUG OR DEVICE.— 
‘‘(i) IN
GENERAL.—If the manufac-
turer of the drug or device is the sponsor 
or a financial sponsor of an applicable clin-
ical trial, and such manufacturer certifies 
to the Director of NIH that such manufac-
turer has filed, or will file within 1 year, 
an application seeking approval under such 
section 505, licensing under such section 
351, clearance under such section 510(k), 
or approval under such section 515 for the 
use studied in such clinical trial (which use 
is not included in the labeling of the ap-
proved drug or device), then the Director 
VerDate Aug 31 2005 
05:37 Jul 12, 2007
Jkt 059200
PO 00000
Frm 00214
Fmt 6652
Sfmt 6201
E:\BILLS\H2900.RH
H2900
bajohnson on PROD1PC77 with BILLS
trative contractors under such part B and commu-
nicated to the appropriate prescription drug plans 
and MA–PD plans and an individual may be initially 
qualified for coverage for such benefit for a 90-day 
period and subsequent 90-day periods thereafter; 
(4) the benefit is modeled on current private 
sector coverage and coding for home infusion ther-
apy; and 
(5) prescription drug plans and MA–PD plans 
structure their formularies, utilization review proto-
cols, and policies in a manner that ensures that 
Medicare beneficiaries have timely and appropriate 
access to infusion therapy in their homes. 
(b) HOME INFUSION THERAPY ADVISORY PANEL.— 
In implementing such home infusion therapy benefit and 
meeting the objectives specified in subsection (a), the Sec-
retary shall establish an advisory panel comprised of quali-
fied home infusion therapy providers and their representa-
tive organizations as well as representatives of the fol-
lowing to provide advice and recommendations: 
(1) Patient organizations. 
(2) Hospital discharge planners, care coordina-
tors or social workers. 
(3) Prescription drug plan sponsors and Medi-
care Advantage organizations. 
VerDate Aug 31 2005 
23:43 Jun 06, 2007
Jkt 059200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H2567.IH
H2567
mstockstill on PROD1PC66 with BILLS
(c) REPORT.—Not later than January 1, 2010, and 
every two years thereafter, the Comptroller General of the 
United States shall submit a report to Congress on Medi-
care beneficiary access to home infusion therapy. Each 
such report shall specifically address whether the objec-
tives specified in subsection (a) have been met and shall 
make recommendations to Congress and the Secretary on 
how to improve the benefit and better ensure that Medi-
care beneficiaries have timely and appropriate access to 
infusion therapy in their homes. 
SEC. 5. EFFECTIVE DATE. 
The amendments made by this Act shall apply to 
home infusion therapy furnished on or after January 1, 
2008. 
Æ 
VerDate Aug 31 2005 
23:43 Jun 06, 2007
Jkt 059200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6301
E:\BILLS\H2567.IH
H2567
mstockstill on PROD1PC66 with BILLS
IV 
110TH CONGRESS 
2D SESSION 
H. RES. 1020 
Recognizing the tremendous service that members of the Armed Forces have 
given to the Nation, especially those who have been wounded in combat. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 4, 2008 
Mr. WELCH of Vermont (for himself, Mr. HIGGINS, Mr. TIAHRT, and Mr. 
WALBERG) submitted the following resolution; which was referred to the 
Committee on Armed Services 
RESOLUTION 
Recognizing the tremendous service that members of the 
Armed Forces have given to the Nation, especially those 
who have been wounded in combat. 
Whereas United States soldiers, sailors, airmen, Marines, and 
their families have made extraordinary sacrifices to serve 
our country in Afghanistan and Iraq; 
Whereas more than 1,600,000 members of the Armed Forces 
of the United States have been deployed in Operation 
Enduring Freedom or Operation Iraqi Freedom since 
September 2001; 
Whereas more than 30,000 soldiers, sailors, airmen, and Ma-
rines have been wounded in battle; 
Whereas advances in battlefield medicine have resulted in 
hundreds of lives being saved; 
VerDate Aug 31 2005 
03:44 Mar 05, 2008
Jkt 069200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR1020.IH
HR1020
smartinez on PRODPC61 with BILLS
219 
original submissions or of any preceding updates, and that 
information in such databases is presented in a manner 
that enables users to readily access each original submis-
sion and to track the changes made by the updates. 
‘‘(e) COORDINATION AND COMPLIANCE.— 
‘‘(1) CONSULTATION
WITH
OTHER
FEDERAL 
AGENCIES.—The Secretary shall— 
‘‘(A) consult with other agencies that con-
duct human studies in accordance with part 46 
of title 45, Code of Federal Regulations (or any 
successor regulations), to determine if any such 
studies are applicable clinical trials; and 
‘‘(B) develop with such agencies appro-
priate procedures to ensure that clinical trial in-
formation for such applicable clinical trials is 
submitted under subsection (b) and (c). 
‘‘(2) COORDINATION
OF
REGISTRY
DATABASE 
AND RESULTS DATABASE.— 
‘‘(A) IN GENERAL.—Each entry in the reg-
istry database under subsection (b) or the re-
sults database under subsection (c) shall in-
clude a link to the corresponding entry in the 
results database or the registry database, re-
spectively. 
‘‘(B) MISSING ENTRIES.— 
VerDate Aug 31 2005 
05:37 Jul 12, 2007
Jkt 059200
PO 00000
Frm 00219
Fmt 6652
Sfmt 6201
E:\BILLS\H2900.RH
H2900
bajohnson on PROD1PC77 with BILLS
220 
‘‘(i) IN GENERAL.—If, based on a re-
view of the entries in the registry database 
under subsection (b), the Director of NIH 
determines that a responsible party has 
failed to submit required clinical trial in-
formation to the results database under 
subsection (c), the Director of NIH shall 
inform the responsible party involved of 
such failure and permit the responsible 
party to correct the failure within 30 days. 
‘‘(ii) FAILURE TO CORRECT.—If the 
responsible party does not correct a failure 
to submit required clinical trial informa-
tion within the 30-day period described 
under clause (i), the Director of NIH shall 
report such noncompliance to the scientific 
peer review committees of the Federal re-
search agencies and to the Office of 
Human Research Protections. 
‘‘(iii) PUBLIC NOTICE OF FAILURE TO 
CORRECT.—The Director of NIH shall in-
clude in the clinical trial registry database 
entry and the clinical trial results database 
entry for each applicable clinical trial a no-
tice of any uncorrected failure to submit 
VerDate Aug 31 2005 
05:37 Jul 12, 2007
Jkt 059200
PO 00000
Frm 00220
Fmt 6652
Sfmt 6201
E:\BILLS\H2900.RH
H2900
bajohnson on PROD1PC77 with BILLS
H. Res. 1021 
In the House of Representatives, U. S., 
April 1, 2008. 
Whereas the purpose of National Women’s History Month is 
to increase awareness and knowledge of women’s involve-
ment in history; 
Whereas as recently as the 1970s, women’s history was rarely 
included in the kindergarten through grade 12 cur-
riculum and was not part of public awareness; 
Whereas the Education Task Force of the Sonoma County 
(California) Commission on the Status of Women initi-
ated a ‘‘Women’s History Week’’ celebration in 1978 cen-
tered around International Women’s History Day, which 
is celebrated on March 8th; 
Whereas in 1981, responding to the growing popularity of 
women’s history celebrations, Congress passed a resolu-
tion making Women’s History Week a national observ-
ance; 
Whereas during this time, using information provided by the 
National Women’s History Project, founded in Sonoma 
County, California, thousands of schools and communities 
joined in the commemoration of National Women’s His-
tory Week, with support and encouragement from gov-
ernors, city councils, school boards, and Congress;
221 
required clinical trial information and shall 
provide that the public may easily search 
for such entries. 
‘‘(3) ACTION ON APPLICATIONS.— 
‘‘(A) VERIFICATION
PRIOR
TO
FILING.— 
The Secretary, acting through the Commis-
sioner of Food and Drugs, shall verify that the 
clinical trial information required under sub-
sections (b) and (c) for an applicable clinical 
trial is submitted pursuant to such subsections, 
as applicable— 
‘‘(i) when considering a drug or device 
for an exemption under section 505(i) or 
section 520(g) of the Federal Food, Drug, 
and Cosmetic Act; and 
‘‘(ii) prior to filing an application or 
premarket notification under section 505, 
510(k), or 515 of the Federal Food, Drug, 
and Cosmetic Act or section 351 of this 
Act, that includes information from such 
clinical trial. 
‘‘(B) NOTIFICATION.—If the Secretary de-
termines under subparagraph (A) that clinical 
trial information has not been submitted as re-
quired by subsection (b) or (c), the Secretary 
VerDate Aug 31 2005 
05:37 Jul 12, 2007
Jkt 059200
PO 00000
Frm 00221
Fmt 6652
Sfmt 6201
E:\BILLS\H2900.RH
H2900
bajohnson on PROD1PC77 with BILLS
226 
$10,000 per day until the violation is corrected 
in the case of any other person, except that if 
the person is a nonprofit entity the penalty may 
not exceed a total of $15,000 for all violations 
adjudicated in a single proceeding. 
‘‘(D) PROCEDURES.—The provisions of 
paragraphs (4) through (6) of section 303(f) of 
the Federal Food, Drug, and Cosmetic Act 
apply to the imposition of a penalty under this 
subsection to the same extent and in the same 
manner as such provisions apply to a penalty 
imposed under such section 303(f). 
‘‘(g) AUTHORIZATION OF APPROPRIATIONS.—There 
are authorized to be appropriated to carry out this section 
$10,000,000 for each fiscal year.’’. 
(b) CONFORMING AMENDMENTS.— 
(1) INVESTIGATIONAL
NEW
DRUGS.—Section 
505(i) of the Federal Food, Drug, and Cosmetic Act 
(21 U.S.C. 355(i)) is amended— 
(A) in paragraph (1)— 
(i) in subparagraph (C), by striking 
‘‘and’’ after the semicolon; 
(ii) in subparagraph (D)— 
(I) by aligning the indentation of 
such subparagraph with the indenta-
VerDate Aug 31 2005 
05:37 Jul 12, 2007
Jkt 059200
PO 00000
Frm 00226
Fmt 6652
Sfmt 6201
E:\BILLS\H2900.RH
H2900
bajohnson on PROD1PC77 with BILLS
227 
tion of subparagraphs (A), (B), and 
(C); and 
(II) by striking the period at the 
end and inserting ‘‘; and’’; and 
(iii) by adding at the end the fol-
lowing: 
‘‘(E) the submission to the Director of NIH of 
clinical trial information for the clinical investigation 
at issue required under section 492C of the Public 
Health Service Act for inclusion in the registry data-
base and the results database described in such sec-
tion.’’; 
(B) in paragraph (3)(B)— 
(i) in clause (i), by striking ‘‘or’’ after 
the semicolon; 
(ii) in clause (ii), by striking the pe-
riod at the end and inserting ‘‘; or’’; and 
(iii) by adding at the end the fol-
lowing: 
‘‘(iii) clinical trial information for the clinical 
investigation at issue was not submitted in compli-
ance with section 492C of the Public Health Service 
Act.’’; and 
(C) in paragraph (4), by adding at the end 
the following: ‘‘The Secretary shall update such 
VerDate Aug 31 2005 
05:37 Jul 12, 2007
Jkt 059200
PO 00000
Frm 00227
Fmt 6652
Sfmt 6201
E:\BILLS\H2900.RH
H2900
bajohnson on PROD1PC77 with BILLS
110TH CONGRESS 
1ST SESSION H. R. 2570 
AN ACT 
To designate the facility of the United States Postal Service 
located at 301 Boardwalk Drive in Fort Collins, Colo-
rado, as the ‘‘Dr. Karl E. Carson Post Office Building’’. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
SECTION 1. DR. KARL E. CARSON POST OFFICE BUILDING. 
(a) DESIGNATION.—The facility of the United States 
Postal Service located at 301 Boardwalk Drive in Fort 
Collins, Colorado, shall be known and designated as the 
‘‘Dr. Karl E. Carson Post Office Building’’. 
(b) REFERENCES.—Any reference in a law, map, reg-
ulation, document, paper, or other record of the United 
States to the facility referred to in subsection (a) shall 
be deemed to be a reference to the ‘‘Dr. Karl E. Carson 
Post Office Building’’. 
Passed the House of Representatives July 16, 2007. 
Attest: 
Clerk.
110TH CONGRESS 
1ST SESSION 
H. R. 2570 
AN ACT 
To designate the facility of the United States Post-
al Service located at 301 Boardwalk Drive in 
Fort Collins, Colorado, as the ‘‘Dr. Karl E. Car-
son Post Office Building’’.
228 
regulations to require inclusion in the informed 
consent form a statement that clinical trial in-
formation for such clinical investigation will be 
submitted for inclusion in the registry database 
and results database, as applicable, described in 
section 492C of the Public Health Service 
Act.’’. 
(2) REFUSAL TO APPROVE NEW DRUG APPLICA-
TION.—Section 505(d) of the Federal Food, Drug, 
and Cosmetic Act (21 U.S.C. 355(d)) is amended— 
(A) in the first sentence, by inserting after 
‘‘in any particular;’’ the following: ‘‘or (8) the 
applicant failed to submit the clinical trial in-
formation for any applicable clinical trial as re-
quired by section 492C of the Public Health 
Service Act;’’; and 
(B) in the second sentence, by striking 
‘‘clauses (1) through (6)’’ and inserting ‘‘para-
graphs (1) through (8)’’. 
(3) INVESTIGATIONAL
NEW
DEVICES.—Sub-
paragraph (B) of section 520(g)(2) of the Federal 
Food, 
Drug, 
and 
Cosmetic 
Act 
(21 
U.S.C. 
360j(g)(2)) is amended— 
(A) by redesignating clause (iii) as clause 
(iv); and 
VerDate Aug 31 2005 
05:37 Jul 12, 2007
Jkt 059200
PO 00000
Frm 00228
Fmt 6652
Sfmt 6201
E:\BILLS\H2900.RH
H2900
bajohnson on PROD1PC77 with BILLS
229 
(B) by inserting after clause (ii) the fol-
lowing: 
‘‘(iii) A requirement that the person applying 
for an exemption for a device assure that such per-
son is in compliance with the requirements of section 
492C of the Public Health Service Act for the sub-
mission of clinical trial information for inclusion in 
the registry database and the results database de-
scribed in such section.’’. 
(4) REFUSAL
TO
CLEAR
NEW
DEVICE
PRE-
MARKET NOTIFICATION REPORT.—Subsection (k) of 
section 510 of the Federal Food, Drug, and Cos-
metic Act (21 U.S.C. 360) is amended— 
(A) in paragraph (1), by striking ‘‘and’’ at 
the end; and 
(B) in paragraph (2), by striking the pe-
riod at the end and inserting ‘‘, and’’; and 
(C) by adding at the end the following: 
‘‘(3) action taken by such person to comply 
with requirements under section 492C of the Public 
Health Service Act for the submission of clinical 
trial information for inclusion in the registry data-
base and the results database described in such sec-
tion.’’. 
VerDate Aug 31 2005 
05:37 Jul 12, 2007
Jkt 059200
PO 00000
Frm 00229
Fmt 6652
Sfmt 6201
E:\BILLS\H2900.RH
H2900
bajohnson on PROD1PC77 with BILLS
H. R. 2570 
One Hundred Tenth Congress 
of the 
United States of America 
AT THE FIRST SESSION 
Begun and held at the City of Washington on Thursday, 
the fourth day of January, two thousand and seven 
An Act 
To designate the facility of the United States Postal Service located at 301 Boardwalk 
Drive in Fort Collins, Colorado, as the ‘‘Dr. Karl E. Carson Post Office Building’’. 
Be it enacted by the Senate and House of Representatives of 
the United States of America in Congress assembled, 
SECTION 1. DR. KARL E. CARSON POST OFFICE BUILDING. 
(a) DESIGNATION.—The facility of the United States Postal 
Service located at 301 Boardwalk Drive in Fort Collins, Colorado, 
shall be known and designated as the ‘‘Dr. Karl E. Carson Post 
Office Building’’. 
(b) REFERENCES.—Any reference in a law, map, regulation, 
document, paper, or other record of the United States to the facility 
referred to in subsection (a) shall be deemed to be a reference 
to the ‘‘Dr. Karl E. Carson Post Office Building’’. 
Speaker of the House of Representatives. 
Vice President of the United States and
President of the Senate.